ReviewClinical journal of the American Society of Nephrology : CJASN2022
Review in Clinical journal of the American Society of Nephrology : CJASN, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Kidney care in patients with cancer: perspectives from the onconephrology committee of the Brazilian Society of Nephrology.Revista da Associacao Medica Brasileira (1992) · 2024Guideline
- Multimodal ultrasound in renal transplantation: a pictorial essay on graft complications.Journal of ultrasound · 2026Review
- Comparison of Clinical Outcomes of Upper Tract Urothelial Carcinoma between Patients after Renal Transplantation and on Dialysis: A Long-Term Single-Center Cohort Study.Annals of surgical oncology · 2026Article
- Ten tips for kidney biopsy in cancer patients.Clinical kidney journal · 2026Review
- Gemcitabine-sirolimus synergy associated thrombotic microangiopathy in a renal transplant recipient with mesenteric leiomyosarcoma: A case report.World journal of transplantation · 2026Article
- Renal Cell Carcinoma of Native Kidneys in Kidney Allograft Recipients: Are There Any Guidelines for Management?Journal of clinical medicine · 2026Article
- Believing in the Nobel Prize: Long-term Success After HLA-Identical Kidney Transplantation in 3 Monozygotic Twins Without any Induction or Maintenance Immunosuppression.Transplantation direct · 2026Article
- Carcinogenic Medications: A Review of Specific Agents and Molecular Mechanisms of Carcinogenesis.Cancer reports (Hoboken, N.J.) · 2026Review
- Solid masses arising in transplanted kidneys.Abdominal radiology (New York) · 2026Review
- Article
- ABO-incompatible living-donor kidney transplantation is not associated with post-transplant malignancy: a multicenter retrospective study.Clinical and experimental nephrology · 2026Article
- Establishing a core outcome measure for cancer in trials in kidney transplantation: a standardized outcomes in nephrology-kidney transplantation consensus workshop report.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Clinical management of cancer after kidney transplantation.Frontiers in immunology · 2026Review
- Post-transplant malignancies in Taiwanese kidney transplant recipients: incidence, temporal trends, and immunosuppressive risk factors in a two-decade single-center cohort.Frontiers in immunology · 2026Article
- Post-Transplant Double Malignancy: Multiple Myeloma and Papillary Renal Cell Carcinoma-A Case Report.Reports (MDPI) · 2025Article
- Dietary patterns, polygenic risk, and kidney cancer incidence: a UK Biobank cohort study.Journal of translational medicine · 2025Article
- Epidemiological Overview of Colorectal Cancer in Kidney Transplant Recipients: A Systematic Review.Cancers · 2025Review
- Critically Important Cancer Outcomes to Report in Kidney Transplant Trials.Kidney international reports · 2025Article
- [Malignant neoplasms and transplantation].Innere Medizin (Heidelberg, Germany) · 2025Review
- [Medical follow-up after solid organs transplantation].Innere Medizin (Heidelberg, Germany) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is an important outcome after kidney transplantation because it is the second leading cause of death in most Western countries. The excess risk of cancer after transplantation is approximately two to three times higher than the age- and sex-matched general population, driven largely by viral- and immune-related cancers. Once cancer develops, outcomes are generally poor, particularly for those with melanoma, renal cell carcinoma, and post-transplant lymphoproliferative disease. More importantly, effective screening and treatment strategies are limited in this high-risk population. In this review, we begin with a patient's journey that maps the experience of living with a kidney transplant and understand the patient's knowledge, education, and experience of cancer in the context of transplantation. The epidemiology and burden of cancer in recipients of kidney transplants, along with the up-to-date screening and treatment strategies, are discussed. We also focus on the current understanding of optimal care for recipients of kidney transplants who are living with cancer from the patients' perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.